The advent of immune checkpoint therapy, specifically designed to block the PD-1/PD-L1 interaction by either directly targeting tumor cells or non-specifically revamping the immune system, relies on PD-L1-induced downregulation of the immune mechanism and the resulting suppression of cancer cell growth8,9. Here, PDCD1 is linked to neoplasm.